Note 16 - Segments (Tables)

9 Months Ended

Sep. 30, 2017

Three Months Ended September 30, 201 7	Diagnostics			Therapeutics			Corporate			Total
Tc99m tilmanocept sales revenue :
United State s	$	—		$	—		$	—		$	—
Internationa l		—			—			—			—
Tc99m tilmanocept license revenu e		—			—			—			—
Grant and other revenu e		210,479			13,190			—			223,669
Total revenu e		210,479			13,190			—			223,669
Cost of goods sold, excluding depreciation and amortizatio n		—			—			—			—
Research and development expenses , excluding depreciation and amortization		734,539			140,008			—			874,547
Selling, general and administrative expenses , excluding depreciation and amortization (1)		—			13,359			1,671,022			1,684,381
Depreciation and amortization (2 )		—			—			50,326			50,326
Loss from operations (3 )		(524,060	)		(140,177	)		(1,721,348	)		(2,385,585	)
Other income (4 )		—			—			69,071			69,071
Income tax benefi t		175,496			46,942			553,312			775,750
Net loss from continuing operation s		(348,564	)		(93,235	)		(1,098,965	)		(1,540,764	)
Income from discontinued operations, net of ta x		5,399			—			—			5,399
Gain on sale of discontinued operations, net of ta x		145,877			—			—			145,877
Net los s		(197,288	)		(93,235	)		(1,098,965	)		(1,389,488	)
Total assets, net of depreciation and amortization :
United State s		14,675,489			10,591			7,835,426			22,521,506
Internationa l		82,334			—			1,867			84,201
Capital expenditures		—			—			23,247			23,247

Three Months Ended September 30 , 2016	Diagnostics		Therapeutics			Corporate			Total
Tc99m tilmanocept sales revenue:
United States	$	—	$	—		$	—		$	—
International		17,601		—			—			17,601
Tc99m tilmanocept license revenue		1,295,625		—			—			1,295,625
Grant and other revenue		500,628		10,346			—			510,974
Total revenue		1,813,854		10,346			—			1,824,200
Cost of goods sold, excluding depreciation and amortization		2,889		—			—			2,889
Research and development expenses, excluding depreciation and amortization		671,777		247,664			—			919,441
Selling, general and administrative expenses, excluding depreciation and amortization ( 1 )		—		27,758			1,694,073			1,721,831
Depreciation and amortization ( 2 )		—		—			89,849			89,849
Income (l oss) from operations ( 3 )		1,139,188		(265,076	)		(1,783,922	)		(909,810	)
Other expenses ( 4 )		—		—			(851,637	)		(851,637	)
Net income (loss) from continuing operations		1,139,188		(265,076	)		(2,635,559	)		(1,761,447	)
Income from discontinued operations, net of tax		1,701,911		—			—			1,701,911
Net income (loss)		2,841,099		(265,076	)		(2,635,559	)		(59,536	)
Total assets, net of depreciation and amortization:
United States		4,950,756		9,356			6,080,567			11,040,679
International		148,224		—			697			148,921
Capital expenditures		—		—			—			—

Nine Months Ended September 30, 2017	Diagnostics			Therapeutics			Corporate			Total
Tc99m tilmanocept sales revenue:
United States	$	—		$	—		$	—		$	—
International		—			—			—			—
Tc99m tilmanocept license revenue		100,000			—			—			100,000
Grant and other revenue		1,200,216			115,082			—			1,315,298
Total revenue		1,300,216			115,082			—			1,415,298
Cost of goods sold, excluding depreciation and amortization		—			—			—			—
Research and development expenses, excluding depreciation and amortization		2,255,842			509,853			—			2,765,695
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			19,342			8,789,728			8,809,070
Depreciation and amortization (2)		—			—			197,655			197,655
L oss from operations (3)		(955,626	)		(414,113	)		(8,987,383	)		(10,357,122	)
Other expenses (4)		—			—			(1,061,190	)		(1,061,190	)
Income tax benefit		323,149			140,034			3,397,972			3,861,156
Net loss from continuing operations		(632,477	)		(274,079	)		(6,650,601	)		(7,557,156	)
Loss from discontinued operations, net of tax		(332,838	)		—			—			(332,838	)
Gain on sale of discontinued operations, net of tax		86,894,000			—			—			86,894,000
Net income (loss)		85,928,685			(274,079	)		(6,650,601	)		79,004,006
Total assets, net of depreciation and amortization:
United States		14,675,489			10,591			7,835,426			22,521,506
International		82,334			—			1,867			84,201
Capital expenditures		—			—			31,417			31,417

Nine Months Ended September 30 , 2016	Diagnostics			Therapeutics			Corporate			Total
Tc99m tilmanocept sales revenue:
United States	$	—		$	—		$	—		$	—
International		30,800			—			—			30,800
Tc99m tilmanocept license revenue		1,795,625			—			—			1,795,625
Grant and other revenue		2,051,622			61,798			—			2,113,420
Total revenue		3,878,047			61,798			—			3,939,845
Cost of goods sold, excluding depreciation and amortization		5,185			—			—			5,185
Research and development expenses, excluding depreciation and amortization		4,410,133			600,790			—			5,010,923
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			31,590			5,542,034			5,573,624
Depreciation and amortization (2)		—			—			258,999			258,999
Loss from operations (3)		(537,271	)		(570,582	)		(5,801,033	)		(6,908,886	)
Other income, excluding equity in loss of R-NAV, LLC (4)		—			—			1,664,265			1,664,265
Equity in loss of R-NAV, LLC		—			—			(15,159	)		(15,159	)
Net loss from continuing operations		(537,271	)		(570,582	)		(4,151,927	)		(5,259,780	)
Loss from discontinued operations, net of tax		(5,167,312	)		—			—			(5,167,312	)
Net loss		(5,704,583	)		(570,582	)		(4,151,927	)		(10,427,092	)
Total assets, net of depreciation and amortization:
United States		4,950,756			9,356			6,080,567			11,040,679
International		148,224			—			697			148,921
Capital expenditures		—			—			1,847			1,847